TACSTD2 and neoplasm: To date, the development of anti-Trop-2 theranostic strategies mainly utilize conventional monoclonal antibodies to inhibit tumor growth, or construct ADC to target the tumor cells with specific antibodies and play the inhibitory role through the conjugated chemicals.